Key result
Review outlines OAC and antiplatelet strategies for post-MI patients with acute ischemic stroke.
Why the study?
The coexistence of AF, ACS, and stroke presents a complex scenario balancing thrombotic and hemorrhagic risks, while trials of new antithrombotic drugs and dual/triple pathways have introduced new therapeutic options.
This review outlines therapeutic strategies for managing complex antithrombotic regimens in post-myocardial infarction patients who experience an acute ischemic stroke, balancing thrombotic and hemorrhagic risks.
May guide individualized antithrombotic regimens in post-MI stroke patients with or without AF; leaves open need for dedicated RCTs.
The association between atrial fibrillation (AF), acute coronary syndrome (ACS), and stroke is a complex scenario in which the assessment of both thrombotic and hemorrhagic risk is necessary for scheduling an individually tailored therapeutic plan. Recent clinical trials investigating new antithrombotic drugs and dual and triple pathways in high-risk cardiovascular patients have revealed a new therapeutic scenario. In this paper, we review the burden of ischemic stroke (IS) in patients post-myocardial infarction with and without atrial fibrillation and the possible therapeutic strategies from a stroke point of view.
No takes yet. Share an insight, caveat, or question.
Pezzella et al. (2022) conducted a review in Post-myocardial infarction with acute ischemic stroke with and without atrial fibrillation. Oral anticoagulation and antiplatelet therapy was evaluated. This review outlines therapeutic strategies for managing oral anticoagulation and antiplatelet therapy in post-myocardial infarction patients with acute ischemic stroke, with and without AF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: